There has been much speculation among the 175 practices still taking part in the OCM what will happen when the 5-year model expires in 2021. The RFI document states that the Oncology Care First model would start in January 2021, “when no new episodes would be initiating in OCM.”
A blood test showcased potential efficacy for screening and detection of breast cancer, according to an abstract to be presented at the 2019 NCRI Cancer Conference.
A review evaluating the methodological approaches of identifying chronic obstructive pulmonary disease (COPD) found that when more criteria is combined, the more accurate the detection of COPD in terms of sensitivity and specificity.
Gut microbiome composition, sleep physiology, the immune system, and cognition were found to be interlinked, indicating possible therapies of gut microbiome manipulation to improve sleep quality, according to study findings.
Microsoft is partnering with an independent, nonprofit biomedical research institution on an artificial intelligence, machine learning tool to process the vast amount of data flowing out of genomic research.
Authors led by Justin Carrico of RTI Health Solutions compared 9 different biologics and the oral drug apremilast in treatment of psoriasis; their anaylsis, “from a US health plan’s perspective,” involved both base cost and cost-effectiveness models that included adverse events.
Intranasal lidocaine may be a useful option for patients with an acute migraine, according to a study which showed the drug had a high success rate, low pain intensity, infrequent need for rescue medicine, and tolerable adverse events.
The Personal KinetiGraph (PKG) Movement Recording System may be effective for routine clinical care of patients with Parkinson disease (PD), according to a recent study.
The cost and care implications of osteoporosis are expected to grow substantially as the baby boomers age. A study published this year found the total annual cost of providing care for osteoporotic fractures among Medicare beneficiaries, including direct medical costs as well as indirect societal costs related to productivity losses and informal caregiving, would rise from $57 billion in 2018 to $95 billion in 2040 unless strategies are implemented to prevent fractures.
Greater non-motor symptom burden may be associated with thalamic atrophy in Parkinson disease (PD), suggesting that the thalamus has a significant role in processing sensory information including visceral afferent from the gastrointestinal tract and regulating states of sleep.
Highmark announced this week that its outcomes-based contract with AstraZeneca for the respiratory combination medication of budesonide/formoterol (Symbicort) revealed positive results in improving outcomes for those with asthma and chronic obstructive pulmonary disease (COPD).
The Trump administration is supporting Stephen Hahn, MD, FASTRO, the chief medical officer of MD Anderson Cancer Center, as the next FDA commissioner, and the current acting commissioner, Ned Sharpless, MD, is returning to his old job as head of the National Cancer Institute (NCI).
This week, the top managed care stories included a report from the FDA considering how to avoid drug shortages; a white paper finds rising comfort with telehealth even as use of digital health tools stagnates; data show a spike in the number of uninsured children.
Broad population-based genomic screening has the potential to improve patient care by detecting genetic causes of disease before they occur; however, the economics behind this approach have not fully been validated, according to a session on the clinical and economic utility of whole-genome sequencing at the AMCP Nexus 2019 meeting.
An analysis of a carrier-based mandatory obstructive sleep apnea (OSA) program on truckers’ non–OSA-program medical insurance claim costs revealed substantial healthcare cost savings, according to study findings.
Rising rates of obesity and diabetes have raised concerns that more people could be headed for end-stage renal disease (ESRD); thus, Medicare has been seeking ways to reduce the cost of care and to improve the quality of life for people on dialysis. Scientists are focusing on whether more patients with early-stage type 2 diabetes should take sodium glucose co-transporter 2 inhibitors, which have been shown to slow renal decline.
Two studies report that children who get measles are more susceptible to other illnesses later; Indiana decides not to pursuue Medicaid work requirements; a Trump administration rule taking effect mandating health insurance for new immigrants is causing confusion.
Panelists YuQian Liu, PharmD, and Carly Rodriguez, PharmD, FAMCP, discussed migraine treatment advances, available real-world evidence, and migraine management strategies with moderator Charles Collins, MS, MBA, at AMCP Nexus 2019 in National Harbor, Maryland.
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Here are the top 5 articles for the month of October.
Although eculizumab is only approved by the FDA to treat 3 rare indications, the high and increasing net sales for the drug have raised concerns about off-label use, according to a research letter in JAMA Internal Medicine.
A new review published in The Lancet describes the future landscape of therapeutics in development for what the authors call the next generation of HIV prevention, or PrEP 2.0.
As the number of disease-modifying therapies available for multiple sclerosis increases, patients and physicians can struggle to identify the right one for the right patient, highlighting the need for a patient decision aid.
The 19 signers of the letter to HHS Secretary Alex Azar and CMS Administrator Seema Verma include Senate Finance Committee members and lawmakers from states with high rates of diabetes and obesity.
Reducing the use of metered-dose inhalers for asthma could shrink the carbon footprint while achieving cost savings if less expensive brands of dry powder inhalers are used, according to new research findings.
A lawsuit filed by a former executive of Juul claims they knowingly sold 1 million contaminated pods; Novartis trial for its Zolgensma gene therapy stopped amid safety concerns; charts show worsening air quality in Louisiana.
Here are 5 interesting findings from the October 2019 issue of AJMC®.
A report released this week by the Kaiser Family Foundation illustrates how immigration policy changes at the federal level are affecting an increasing number of families, some of whom are disenrolling themselves and their children from California’s Medicaid program and not renewing or not enrolling in other programs, even though they are eligible and not directly affected by the policy changes. Experts are worried about long-term health effects.
The FDA today approved Biogen and Alkermes’ diroximel fumarate, an oral agent, to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and secondary progressive disease. The drug, approved under the 505(b)(2) regulatory pathway on the basis of its bioequivalence to dimethyl fumarate (Tecfidera), will be sold as Vumerity.
The number of uninsured children in the United States rose by more than 400,000 between 2016 and 2018 and now stands at over 4 million; mortality from heart failure rose 20.7% between 2011 and 2017 and is likely to keep climbing sharply; US District Judge Myron Thompson issued a preliminary injunction temporarily blocking Alabama from enforcing a near-total abortion ban.